Evidence map›Paper›PMID 34680354›Full record

ReviewCancers2021

The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications.

Steven F Powell, Lexi Vu, William C Spanos, Dohun Pyeon

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  17. Review
  18. Review
  19. Article
  20. HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology.International journal of molecular sciences · 2025
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Steven F PowellCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA.
Lexi VuDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.ORCID 0000-0001-9243-7469
William C SpanosCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA.
Dohun PyeonDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.ORCID 0000-0003-1970-844X
Michigan State University · USSanford Research · US

Funding

Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancerR01DE029524 · NIDCR · MICHIGAN STATE UNIVERSITY · PI PYEON, DOHUN, SPANOS, WILLIAM CHARLES · 2020 to 2024
$3.2M
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer ProgressionR01DE026125 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI PYEON, DOHUN, SPANOS, WILLIAM CHARLES · 2016 to 2020
$2.8M
NIDCR NIH HHS R01 DE026125NIDCR NIH HHS R01 DE029524NIH HHS R01 DE026125NIH HHS R01 DE029524
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a unique malignancy associated with two distinct risk factors: exposure to typical carcinogens and infection of human papillomavirus (HPV). HPV encodes the potent oncoproteins E6 and E7, which bypass many important oncogenic processes and result in cancer development. In contrast, HPV-negative HNSCC is developed through multiple mutations in diverse oncogenic driver genes. While the risk factors associated with HPV-positive and HPV-negative HNSCCs are discrete, HNSCC patients still show highly complex molecular signatures, immune infiltrations, and treatment responses even within the same anatomical subtypes. Here, we summarize the current understanding of biological mechanisms, treatment approaches, and clinical outcomes in comparison between HPV-positive and -negative HNSCCs.

Indexed as

clinical outcomeclinical trialsde-escalation strategieshead and neck cancerhead and neck squamous cell carcinomahuman papillomavirusmicrobiomemolecular carcinogenesissurgerytreatmenttumor microenvironment

Identifiers

PMID34680354
PMCPMC8533896
OpenAlexW3207811959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.